These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34637026)

  • 1. Rationale for MYC imaging and targeting in pancreatic cancer.
    Schneider G; Wirth M; Keller U; Saur D
    EJNMMI Res; 2021 Oct; 11(1):104. PubMed ID: 34637026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.
    Lankes K; Hassan Z; Doffo MJ; Schneeweis C; Lier S; Öllinger R; Rad R; Krämer OH; Keller U; Saur D; Reichert M; Schneider G; Wirth M
    Mol Oncol; 2020 Dec; 14(12):3048-3064. PubMed ID: 33099868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
    Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
    J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concepts to Target MYC in Pancreatic Cancer.
    Wirth M; Mahboobi S; Krämer OH; Schneider G
    Mol Cancer Ther; 2016 Aug; 15(8):1792-8. PubMed ID: 27406986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapeutic trends in pancreatic ductal adenocarcinoma (PDAC).
    Chandana S; Babiker HM; Mahadevan D
    Expert Opin Investig Drugs; 2019 Feb; 28(2):161-177. PubMed ID: 30539678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.
    Beglyarova N; Banina E; Zhou Y; Mukhamadeeva R; Andrianov G; Bobrov E; Lysenko E; Skobeleva N; Gabitova L; Restifo D; Pressman M; Serebriiskii IG; Hoffman JP; Paz K; Behrens D; Khazak V; Jablonski SA; Golemis EA; Weiner LM; Astsaturov I
    Clin Cancer Res; 2016 Dec; 22(24):6153-6163. PubMed ID: 27384421
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.
    Hessmann E; Schneider G; Ellenrieder V; Siveke JT
    Oncogene; 2016 Mar; 35(13):1609-18. PubMed ID: 26119937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype.
    Biederstädt A; Hassan Z; Schneeweis C; Schick M; Schneider L; Muckenhuber A; Hong Y; Siegers G; Nilsson L; Wirth M; Dantes Z; Steiger K; Schunck K; Langston S; Lenhof HP; Coluccio A; Orben F; Slawska J; Scherger A; Saur D; Müller S; Rad R; Weichert W; Nilsson J; Reichert M; Schneider G; Keller U
    Gut; 2020 Aug; 69(8):1472-1482. PubMed ID: 32001555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreatic Cancer Immuno-oncology in the Era of Precision Medicine.
    Hegde S
    Indian J Surg Oncol; 2021 Apr; 12(Suppl 1):118-127. PubMed ID: 33994737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FASTKD2 promotes cancer cell progression through upregulating Myc expression in pancreatic ductal adenocarcinoma.
    Fang R; Zhang B; Lu X; Jin X; Liu T
    J Cell Biochem; 2020 Mar; 121(3):2458-2466. PubMed ID: 31692063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.
    Wan C; Gong C; Zhang H; Hua L; Li X; Chen X; Chen Y; Ding X; He S; Cao W; Wang Y; Fan S; Xiao Y; Zhou G; Shen A
    Cancer Lett; 2016 Apr; 373(1):67-76. PubMed ID: 26803058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma.
    Wang B; Fan P; Zhao J; Wu H; Jin X; Wu H
    J Exp Clin Cancer Res; 2018 Sep; 37(1):224. PubMed ID: 30201002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-29a Is Repressed by MYC in Pancreatic Cancer and Its Restoration Drives Tumor-Suppressive Effects via Downregulation of LOXL2.
    Dey S; Kwon JJ; Liu S; Hodge GA; Taleb S; Zimmers TA; Wan J; Kota J
    Mol Cancer Res; 2020 Feb; 18(2):311-323. PubMed ID: 31662451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High mobility group AT-hook 2 and c-MYC as potential prognostic factors in pancreatic ductal adenocarcinoma.
    Li K; Yang J; Chen J; Shi Y; Zhang Z; Chen W
    Oncol Lett; 2020 Feb; 19(2):1584-1592. PubMed ID: 31966084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Strategies and Future Perspectives for Precision Medicine in Pancreatic Cancer.
    Regel I; Mayerle J; Mahajan UM
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From Malignant Progression to Therapeutic Targeting: Current Insights of Mesothelin in Pancreatic Ductal Adenocarcinoma.
    Montemagno C; Cassim S; Pouyssegur J; Broisat A; Pagès G
    Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A PET Imaging Strategy for Interrogating Target Engagement and Oncogene Status in Pancreatic Cancer.
    Henry KE; Dacek MM; Dilling TR; Caen JD; Fox IL; Evans MJ; Lewis JS
    Clin Cancer Res; 2019 Jan; 25(1):166-176. PubMed ID: 30228208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LINC00346 promotes pancreatic cancer progression through the CTCF-mediated Myc transcription.
    Peng WX; He RZ; Zhang Z; Yang L; Mo YY
    Oncogene; 2019 Oct; 38(41):6770-6780. PubMed ID: 31391552
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrant expression of PDZ-binding kinase/T-LAK cell-originated protein kinase modulates the invasive ability of human pancreatic cancer cells via the stabilization of oncoprotein c-MYC.
    Hinzman CP; Aljehane L; Brown-Clay JD; Kallakury B; Sonahara F; Goel A; Trevino J; Banerjee PP
    Carcinogenesis; 2018 Dec; 39(12):1548-1559. PubMed ID: 30165468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pancreatic Cancer Organoids for Determining Sensitivity to Bromodomain and Extra-Terminal Inhibitors (BETi).
    Bian B; Juiz NA; Gayet O; Bigonnet M; Brandone N; Roques J; Cros J; Wang N; Dusetti N; Iovanna J
    Front Oncol; 2019; 9():475. PubMed ID: 31231611
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.